Paliperidone Teva Pharma (Paliperidone Palmitate)

Paliperidone palmitate, the active ingredient in Paliperidone Teva Pharma, is a atypical antipsychotic presented as a long‑acting injectable suspension for intramuscular use. It is indicated for the treatment of schizophrenia in adult patients. GNH USA supplies Paliperidone Teva Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Paliperidone Teva Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Paliperidone palmitate is a long‑acting injectable antipsychotic that works within the dopamine‑serotonin pathway to manage psychotic disorders.

- Schizophrenia: helps reduce the frequency of relapse and maintain symptom control in adults. - Schizoaffective disorder: contributes to stabilization of mood and psychotic symptoms when used as part of a comprehensive treatment plan. - Maintenance therapy after acute episode: provides sustained medication levels to support ongoing management after an initial stabilization phase.

Paliperidone palmitate may cause a range of adverse reactions, most of which are dose‑dependent and often diminish over time.

Common Side Effects: - Injection site pain or erythema - Headache - Fatigue - Restlessness (akathisia) - Nausea - Weight gain

Serious or Rare Side Effects: - Neuroleptic malignant syndrome - Tardive dyskinesia - Severe orthostatic hypotension - Hyperglycaemia or new‑onset diabetes mellitus - Seizures - Elevated prolactin levels causing galactorrhoea or menstrual disturbances

When prescribing Paliperidone Teva Pharma, clinicians should consider several safety aspects.

- Cardiovascular assessment: evaluate for history of arrhythmias or QT prolongation. - Metabolic monitoring: check blood glucose and lipid profiles regularly. - Movement disorders: observe for signs of tardive dyskinesia or akathisia. - Pregnancy and lactation: weigh potential benefits against risks; use only if clearly needed. - Elderly patients: start at lower doses and monitor for orthostatic hypotension. - Store at room temperature: keep in original packaging, protect from moisture and light.

Paliperidone palmitate can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase paliperidone exposure. - CNS depressants (e.g., benzodiazepines, opioids): additive sedation and respiratory depression risk.

Moderate Interactions (Monitor Closely):\n- Antihypertensives: may enhance orthostatic hypotension. - Antidiabetic agents: potential for altered glucose control. - Other antipsychotics: increased risk of QT prolongation and extrapyramidal symptoms.